Trial Profile
A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Affitope PD03 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors AFFiRiS
- 07 Jun 2017 Top Line results from this study published in an AFFiRiS Media Release.
- 07 Jun 2017 According to an AFFiRiS media release, data from this trial were presented at the 21st International Congress of Parkinsons Disease and Movement Disorders.
- 28 Oct 2016 Status changed from active, no longer recruiting to completed.